Fajgenbaum DC, Uldrick TS, Bagg A et al (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646–1657. https://doi.org/10.1182/blood-2016-10-746933

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dispenzieri A, Fajgenbaum DC (2020) Overview of Castleman disease. Blood 135:1353–1364. https://doi.org/10.1182/blood.2019000931

Article  PubMed  Google Scholar 

Sasaki T, Akiyama M, Kaneko Y, Takeuchi T (2022) Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders. Rheumatology (Oxford) 61:490–501. https://doi.org/10.1093/rheumatology/keab634

Article  CAS  PubMed  Google Scholar 

Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K (2019) A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman’s disease. Mod Rheumatol 29:302–305. https://doi.org/10.1080/14397595.2018.1532383

Article  CAS  PubMed  Google Scholar 

Liu AY, Nabel CS, Finkelman BS et al (2016) Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol 3:e163–e175. https://doi.org/10.1016/S2352-3026(16)00006-5

Article  PubMed  Google Scholar 

Casper C, Chaturvedi S, Munshi N et al (2015) Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of Siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease. Clin Cancer Res 21:4294–4304. https://doi.org/10.1158/1078-0432.CCR-15-0134

Article  CAS  PubMed  Google Scholar 

González García A, Fernández-Martín J, Robles Marhuenda Á (2023) Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford) 62:1426–1435. https://doi.org/10.1093/rheumatology/keac481

Article  PubMed  Google Scholar 

Hashizume M, Uchiyama Y, Horai N et al (2010) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced Hepcidin production. Rheumatol Int 30:917–923. https://doi.org/10.1007/s00296-009-1075-4

Article  CAS  PubMed  Google Scholar 

Berentsen Sigbjørn B Wilma (2021) Autoimmune hemolytic anemias. N Engl J Med 385:1407–1419. https://doi.org/10.1056/NEJMra2033982

Article  PubMed  Google Scholar 

Jäger U, Barcellini W, Broome CM et al (2020) Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev 41:100648. https://doi.org/10.1016/j.blre.2019.100648

Article  CAS  PubMed  Google Scholar 

Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632. https://doi.org/10.1182/blood-2004-12-4602

Article  CAS  PubMed  Google Scholar 

van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115–2124. https://doi.org/10.1182/blood-2018-07-862334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akiyama M, Yasuoka H, Takeuchi T (2017) Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term Tocilizumab. Ann Hematol 96:2117–2119. https://doi.org/10.1007/s00277-017-3111-x

Article  CAS  PubMed  Google Scholar 

Nakayama H, Kikuchi T, Abe R et al (2018) Evans syndrome complicated with multicentric Castleman disease successfully treated with Tocilizumab. Rinsho Ketsueki 59:997–1001. https://doi.org/10.11406/rinketsu.59.997

Article  PubMed  Google Scholar 

Kawano M, Hara S, Yachie A et al (2021) HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. Rheumatology (Oxford) 60:e3–e4. https://doi.org/10.1093/rheumatology/keaa362

Article  PubMed  Google Scholar 

Kunitomi A, Konaka Y, Yagita M et al (2004) Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol 80:246–249. https://doi.org/10.1532/ijh97.04058

Article  PubMed  Google Scholar 

Zhao M, Chen L, Yang J et al (2023) Interleukin 6 exacerbates the progression of warm autoimmune hemolytic anemia by influencing the activity and function of B cells. Sci Rep 13:13231. https://doi.org/10.1038/s41598-023-40239-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishikori A, Nishimura MF, Nishimura Y et al (2022) Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease. Int J Mol Sci 23:10301. https://doi.org/10.3390/ijms231810301

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benlidayi IC, Gupta L (2024) CAse-BAsed review sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https://doi.org/10.3346/jkms.2024.39.e225

Article  PubMed  PubMed Central  Google Scholar 

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3

Article  PubMed  Google Scholar 

Yuzuriha A, Saitoh T, Koiso H et al (2011) Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol 126:147–150. https://doi.org/10.1159/000328426

Article  PubMed  Google Scholar 

Plano F, Mancuso S, Camarda GM et al (2024) A multicentric Castleman disease associated with mixed warm and cold antibody-mediated AHA responsive to Siltuximab. Chemotherapy 69:35–39. https://doi.org/10.1159/000533235

Article  CAS  PubMed  Google Scholar 

Tabata S, Higuchi T, Tatsukawa S et al (2019) Idiopathic multicentric Castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against Tocilizumab. Intern Med 58:3313–3318. https://doi.org/10.2169/internalmedicine.2989-19

Article  PubMed  PubMed Central  Google Scholar 

Sansen P-Y, Vellemans H, Depaus J et al (2024) An unusual case of HHV-8 negative, idiopathic, multicentric Castleman disease following chronic lymphocytic leukaemia. Eur J Case Rep Intern Med 11:004688. https://doi.org/10.12890/2024_004688

Article  PubMed  PubMed Central  Google Scholar 

Yoshizaki K, Murayama S, Ito H, Koga T (2018) The role of interleukin-6 in Castleman disease. Hematol Oncol Clin North Am 32:23–36. https://doi.org/10.1016/j.hoc.2017.09.003

Article  PubMed  Google Scholar 

Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360–1367. https://doi.org/10.1182/blood.v74.4.1360.bloodjournal7441360

Article  CAS  PubMed  Google Scholar 

Eiers A-K, Vettorazzi S, Tuckermann JP (2024) Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases. Ann Rheum Dis 83:1603–1613. https://doi.org/10.1136/ard-2023-225371

Article  CAS  PubMed  Google Scholar 

Michel M, Terriou L, Roudot-Thoraval F et al (2017) A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study): rituximab for wAIHA in adults. Am J Hematol 92:23–27. https://doi.org/10.1002/ajh.24570

Article  CAS  PubMed  Google Scholar 

Nishimura Y, Fajgenbaum DC, Pierson SK et al (2021) Validated international definition of the thrombocytopenia, Anasarca, fev